<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
    <channel>
        <title>Watchdog Transparency Blog - Most recent 5 featured articles</title>
        <description>Most recent 5 articles categorized as 'Featured'</description>
        <link>https://blog.watchdogresearch.com</link>
        <atom:link href="https://blog.watchdogresearch.com/feed.featured.xml" rel="self" type="application/rss+xml" />
        <lastBuildDate>Fri, 12 Mar 2021 10:34:00 -0500</lastBuildDate>


        
        <item>
            <title>The Impact of Securities Lawsuits</title><author>John Cheffers</author>
            
            <category>Impact Analysis</category>
            

            <description>&lt;p&gt;In our research on securities class action lawsuits, we measure the impact the lawsuits by looking at abnormal returns over the 30-day period following a securities lawsuit. We calculate the abnormal returns by comparing how the company performed with how the S&amp;amp;P 500 performed on average over the same 30-day period.&lt;/p&gt;
</description>
            <pubDate>2021-03-12T10:34:00-05:00</pubDate>
            <link>https://blog.watchdogresearch.com/posts/the-impact-of-securities-lawsuits/</link><enclosure url="https://blog.watchdogresearch.com/uploads/SCA%20Histogram.png" length="100000" type="image/jpeg"/><guid isPermaLink="true">https://blog.watchdogresearch.com/posts/the-impact-of-securities-lawsuits/</guid>
        </item>
        
        <item>
            <title>Restatements More Disruptive to Foreign Companies than U.S. Companies</title><author>John Cheffers</author>
            
            <category>Restatements</category>
            

            <description>&lt;p&gt;&lt;em&gt;Investor Confidence in Foreign Companies is More Easily Shaken&lt;/em&gt;&lt;/p&gt;
</description>
            <pubDate>2021-03-05T14:21:00-05:00</pubDate>
            <link>https://blog.watchdogresearch.com/posts/restatements-more-disruptive-for-foreign-companies-than-us-companies/</link><enclosure url="https://blog.watchdogresearch.com/uploads/globe.jpg" length="100000" type="image/jpeg"/><guid isPermaLink="true">https://blog.watchdogresearch.com/posts/restatements-more-disruptive-for-foreign-companies-than-us-companies/</guid>
        </item>
        
        <item>
            <title>2020: U.S. Restatements Fall to 10-Year Low</title><author>John Cheffers</author>
            
            <category>Restatements</category>
            

            <description>&lt;p&gt;&lt;em&gt;U.S. companies filed 42 restatements in 2020, the fewest ever.&lt;/em&gt;&lt;/p&gt;
</description>
            <pubDate>2021-02-26T12:32:00-05:00</pubDate>
            <link>https://blog.watchdogresearch.com/posts/2020-us-restatements-fall-to-10-year-low/</link><enclosure url="https://blog.watchdogresearch.com/uploads/Restatements%20by%20size%20pic-6e1052.jpg" length="100000" type="image/jpeg"/><guid isPermaLink="true">https://blog.watchdogresearch.com/posts/2020-us-restatements-fall-to-10-year-low/</guid>
        </item>
        
        <item>
            <title>Biotech and Pharmaceutical Litigation in 2020</title><author>John Cheffers</author>
            
            <category>Securities Litigation</category>
            

            <description>&lt;p&gt;Companies sustained record-setting levels of securities class action suits in 2017, 2018, and 2019 after the Supreme Court’s decision in &lt;a href=&quot;https://blog.watchdogresearch.com/posts/the-post-cyan-paradigm/&quot;&gt;Cyan&lt;/a&gt; threw open the doors of the state courts to traditionally federal securities litigation. In 2020, the number of securities class action suits filed receded from these all-time highs, but it is unclear whether the reduction is a temporary departure from a new paradigm, or the beginning a of a return to the mean.&lt;/p&gt;
</description>
            <pubDate>2021-02-17T11:13:00-05:00</pubDate>
            <link>https://blog.watchdogresearch.com/posts/biotech-and-pharmaceutical-litigation-in-2020/</link><enclosure url="https://blog.watchdogresearch.com/uploads/Legal-ec0bcb.jpg" length="100000" type="image/jpeg"/><guid isPermaLink="true">https://blog.watchdogresearch.com/posts/biotech-and-pharmaceutical-litigation-in-2020/</guid>
        </item>
        
        <item>
            <title>Review of 2020's High-Risk Companies</title><author>John Cheffers</author>
            
            <category>Red Flags</category>
            

            <description>&lt;p&gt;&lt;em&gt;Five large-cap companies that we categorized as “high-risk” struggled throughout the year.&lt;/em&gt;&lt;/p&gt;
</description>
            <pubDate>2021-02-15T09:27:00-05:00</pubDate>
            <link>https://blog.watchdogresearch.com/posts/review-of-2020-s-high-risk-companies/</link><enclosure url="https://blog.watchdogresearch.com/uploads/Gray%20Swan.jpg" length="100000" type="image/jpeg"/><guid isPermaLink="true">https://blog.watchdogresearch.com/posts/review-of-2020-s-high-risk-companies/</guid>
        </item>
        

    </channel>
</rss>

